Medicare covers Ozempic for type 2 diabetes, cardiovascular disease, and kidney disease in diabetic adults. Coverage for weight loss is not allowed under current federal law, regardless of how a doctor prescribes it.
Most Medicare Part 2 Part D plans include Ozempic on their formulary, but coverage isn’t automatic. Plans require prior authorization, assign the drug to a cost tier, and cap 2026 out-of-pocket costs at $2,100. The list price without insurance is $1,027.51 per monthly injection, though negotiated federal prices arrive in 2027.
This guide covers everything Medicare beneficiaries need to know: which diagnoses qualify, how much Ozempic costs under Part D, what savings programs exist, and how the new GLP-1 Bridge program and 2027 price negotiations change the picture.
What Is Ozempic?
Ozempic is a brand-name injectable medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in 2017. Novo Nordisk manufactures it as a once-weekly self-administered injection prescribed primarily for adults with type 2 diabetes mellitus.
Here’s how it works. Semaglutide mimics a hormone released after eating. That hormone signals the pancreas to produce insulin, which lowers blood sugar. And it slows digestion, which reduces glucose spikes after meals. The result is steadier blood sugar control throughout the day.
Beyond blood sugar control, the FDA has approved Ozempic to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and existing heart disease. A further approval covers kidney and heart health in adults with type 2 diabetes and chronic kidney disease. These three approved uses matter enormously for Medicare coverage.
What Does Ozempic Treat?
Ozempic treats three FDA-approved conditions: type 2 diabetes, cardiovascular disease risk in diabetic patients, and chronic kidney disease in diabetic patients. Each approved indication requires specific clinical documentation from a prescriber.
Weight loss is a commonly reported side effect of Ozempic. Why does that matter? Because weight loss as a side effect is different from weight loss as an approved indication. Wegovy, a higher-dose semaglutide product from the same manufacturer, carries an explicit FDA approval for chronic weight management. Ozempic does not.
That distinction is the single most important fact for any Medicare beneficiary. Payers follow FDA labeling when deciding which uses they reimburse. No diabetes diagnosis on the prescription? No Medicare coverage for the drug.
FDA-approved uses of Ozempic:
- Type 2 diabetes mellitus in adults
- Cardiovascular risk reduction in adults with type 2 diabetes and heart disease
- Kidney and heart health in adults with type 2 diabetes and chronic kidney disease
Does Medicare Cover Ozempic?
Medicare covers Ozempic under Part D prescription drug plans when it is prescribed for its FDA-approved uses: type 2 diabetes, cardiovascular risk reduction, or kidney disease in diabetic adults. Coverage for weight loss is not permitted under current federal law.
Approximately 94 percent of Medicare Part D plans include Ozempic on their formulary. But here’s the part most people miss: formulary inclusion does not guarantee coverage at every pharmacy or for every diagnosis. The plan must verify the diagnosis before approving the prescription. Without that verification step, the claim gets rejected even if the drug appears on the plan’s list.
Medicare Advantage plans follow the same federal rules as Original Medicare. A Medicare Advantage plan cannot override the statutory exclusion of weight loss medications, regardless of what its marketing materials suggest. The prohibition is federal law, not a plan-level policy decision.
Does Medicare Part D Cover Ozempic for Type 2 Diabetes?
Yes. Medicare Part D plans cover Ozempic for type 2 diabetes as a standard formulary drug, classifying it as a Tier 3 or Tier 4 brand-name medication in most plans. Tier placement affects the copay, with higher tiers carrying larger cost-sharing amounts.
Prior authorization is required by most plans before coverage activates. The prescriber submits documentation of the type 2 diabetes diagnosis. The insurer reviews it and approves or denies coverage within the plan’s stated timeframe, typically a few business days.
Once approved, the out-of-pocket maximum for Medicare Part D in 2026 is $2,100 per year. After that threshold, the plan covers 100 percent of drug costs for the remainder of the plan year. For a drug with a list price over $1,000 per month, hitting that cap is realistic for many beneficiaries.
Does Medicare Cover Ozempic for Weight Loss?
No. Federal law prohibits Medicare from covering prescription drugs prescribed solely for weight loss or obesity treatment, and Ozempic is included in that exclusion regardless of how a doctor writes the prescription.
Congress passed that exclusion as part of the original Medicare Modernization Act. Ozempic prescribed off-label for weight loss falls outside the approved indications Medicare will pay for, even if the prescribing doctor believes it is clinically appropriate. The diagnosis on the prescription has to match an FDA-approved use.
So what does that mean for you? If you have type 2 diabetes and your doctor prescribes Ozempic primarily to manage blood sugar, Medicare Part D covers it. If your doctor prescribes Ozempic specifically for weight loss and no diabetes diagnosis exists, Medicare will not cover it.
How Does Medicare Part D Work for Ozempic?
Medicare Part D is the federal prescription drug benefit that covers stand-alone drug plans and the drug component of Medicare Advantage plans, using a tiered formulary structure to determine cost-sharing. Each plan publishes a formulary listing covered drugs and their tier assignments.
Coverage under Part D runs through four stages: the deductible stage, the initial coverage stage, the coverage gap, and catastrophic coverage. In 2026, the out-of-pocket maximum caps total drug spending at $2,100 before catastrophic protection activates.
The four Part D coverage stages in 2026:
- Deductible stage: Pay full cost until the deductible (up to $590) is met
- Initial coverage stage: Pay the plan’s copay or coinsurance rate per tier
- Coverage gap: Costs continue until total out-of-pocket reaches $2,100
- Catastrophic coverage: Plan pays 100 percent for the rest of the year
What Are the Prior Authorization Requirements?
Prior authorization requires a prescriber to submit documentation to the Medicare Part D plan confirming that a patient meets the clinical criteria for Ozempic coverage before the plan will pay for the drug.
For Ozempic, the insurer typically requires evidence of a type 2 diabetes diagnosis, often an HbA1c lab result or a physician’s clinical note. Some plans also require proof that the patient tried a first-line medication, such as metformin, before approving a branded GLP-1 therapy. This is called a step therapy requirement.
If the plan denies prior authorization, the prescriber can file an appeal or submit a peer-to-peer review request. In a peer-to-peer, the prescriber speaks directly with the plan’s medical reviewer to argue the clinical case for coverage. Many denials reverse at the appeal stage.
What Are the Coverage Tiers for Ozempic?
Ozempic sits on Tier 3 or Tier 4 in most Medicare Part D formularies, which means it carries a higher copay than generic Tier 1 and preferred brand Tier 2 drugs. Tier placement varies by plan and changes annually.
Tier 3 represents preferred brand-name drugs with moderate copays. Tier 4 represents non-preferred brands with higher cost-sharing. A plan places Ozempic on either tier depending on its contract negotiations with Novo Nordisk and its overall formulary design for that plan year.
Enrollees check their specific plan’s formulary at Medicare.gov or by calling the plan directly. Formulary placement for the upcoming plan year publishes each October during the annual enrollment period. Switching plans during open enrollment is an option if another plan offers better tier placement for Ozempic.
How Much Does Ozempic Cost With Medicare?
The cost of Ozempic with Medicare Part D depends on the plan’s tier placement, the coverage stage the beneficiary is in, and whether prior authorization has been approved, but the 2026 out-of-pocket cap is $2,100 per year.
Beneficiaries in the deductible stage pay full cost for Ozempic until they meet the annual deductible, which can be up to $590 in 2026. After meeting the deductible, cost-sharing shifts to the plan’s copay or coinsurance rate for the drug’s tier. The difference between a Tier 3 and Tier 4 copay on a drug this expensive can be hundreds of dollars per month.
Ozempic cost comparison by coverage situation:
| Situation | Estimated Monthly Cost |
| No insurance (list price) | $1,027.51 |
| SingleCare coupon (no insurance) | ~$825 |
| Medicare Part D (Tier 3, post-deductible) | Varies by plan |
| Medicare Extra Help (low income subsidy) | Reduced copay |
| After $2,100 out-of-pocket cap (2026) | $0 |
| Medicare-negotiated price (2027) | $274 for 30-day supply |
What Is the Cost of Ozempic Without Insurance?
Ozempic costs $1,027.51 per monthly injection at the manufacturer’s list price, making it one of the more expensive GLP-1 therapies on the market without insurance or assistance programs.
The list price is what Novo Nordisk charges before any negotiations, rebates, or discounts. Most insured patients do not pay list price. Medicare Part D plans negotiate rebates with manufacturers, which lowers the plan’s net cost and influences tier placement. The patient’s actual cost reflects the tier copay after the deductible, not the list price.
Without any insurance, pharmacy discount programs reduce costs. SingleCare’s coupon brings the price to approximately $825 per pen (0.25 mg or 0.5 mg dose, 3 mL prefilled), compared to a typical cash price of $1,393 for the same quantity. That represents roughly a 40 percent savings. SingleCare coupons cannot be combined with Medicare Part D coverage. Ready to speed things up? Get a proven weight loss plan built around these exact principles.
How Can You Lower Ozempic Costs With Medicare?
Medicare beneficiaries with limited income and resources can apply for Medicare Extra Help, a federal program that subsidizes Part D premiums, deductibles, and copays for qualifying individuals who meet income and asset thresholds.
The Medicare Prescription Payment Plan (M3P) lets beneficiaries spread out-of-pocket drug costs across monthly payments throughout the plan year rather than paying large amounts at once. The good news? This option does not require income qualification. It smooths cash flow without reducing total costs.
Novo Nordisk’s Patient Assistance Program (PAP) provides free Ozempic to income-eligible individuals. As of 2026, Medicare Part D recipients no longer qualify for PAP. Those without any prescription drug coverage may still qualify if household income is 200 percent or less of the federal poverty level.
Ozempic savings options for Medicare beneficiaries:
- Medicare Extra Help (low income subsidy for Part D)
- Medicare Prescription Payment Plan (M3P) for spreading costs
- Switching plans during open enrollment for better tier placement
- SingleCare coupon for out-of-pocket purchases (cannot combine with Part D)
- Novo Nordisk PAP (for uninsured individuals below income thresholds)
What Changes Are Coming to Medicare Coverage in 2026 and 2027?
Medicare drug coverage for GLP-1 medications is undergoing major changes through 2027, including a new Bridge program for obesity treatment and federally negotiated prices for semaglutide products taking effect in January 2027.
In January 2025, the Centers for Medicare and Medicaid Services selected Ozempic, Rybelsus, and Wegovy for the second round of Medicare drug price negotiations. Negotiated prices for those three drugs take effect in 2027. The Medicare-negotiated price for the semaglutide class is set at $274 for a 30-day supply. Plans that cover negotiated drugs are required by law to include them in their formularies, so access improves automatically for enrolled beneficiaries.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge program launched in July 2026 and allows qualifying Medicare beneficiaries with obesity to access certain GLP-1 medications at a $50 monthly copay through December 2027, with an estimated 3.8 million people potentially eligible.
The Bridge program has strict medical criteria. Eligible beneficiaries must have a body mass index of 30 or above, or 27 with a weight-related condition such as hypertension or sleep apnea. The program does not include Ozempic, which carries a diabetes rather than weight management approval. Is that distinction frustrating? For beneficiaries who want semaglutide specifically for weight loss, yes.
Wegovy, which contains semaglutide at a higher dose than Ozempic, is included in the Bridge program for obesity and cardiovascular risk. Beneficiaries whose doctors want to use semaglutide for weight loss should ask specifically about Wegovy and its GLP-1 Bridge eligibility. Assuming Ozempic qualifies leads to denied claims and unexpected out-of-pocket costs.
What Are the Side Effects of Ozempic?
Ozempic produces gastrointestinal side effects in a significant proportion of users, with nausea, vomiting, diarrhea, and constipation among the most commonly reported effects, particularly during the initial dose escalation phase.
For older Medicare beneficiaries, the side effect profile carries additional weight. Gastrointestinal effects cause dehydration, which in older adults stresses kidneys and disrupts electrolyte balance. The drug may also contribute to muscle and bone loss when combined with caloric restriction, a concern for patients already at risk for sarcopenia or osteoporosis. Our nutritionists at Eat Proteins always recommend discussing these risks specifically with a geriatric-aware prescriber before starting.
In clinical trials, Ozempic carried a warning for thyroid C-cell tumors, including thyroid cancer, observed in rodent studies. The clinical significance in humans remains under study. Ozempic carries a black box warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
Common Ozempic side effects:
- Nausea (most common, especially during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Dehydration risk in older adults
- Possible muscle and bone loss with caloric restriction
Who Should Avoid Ozempic?
Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a known hypersensitivity to semaglutide or any ingredient in the formulation.
Patients with a history of pancreatitis require careful evaluation before starting Ozempic. The drug has been associated with acute pancreatitis in post-marketing reports. Prescribers weigh the cardiovascular and glycemic benefits against this risk individually. Here’s the thing: the benefit-risk calculation looks different for every patient, and there is no universal answer.
Drug interactions require review before starting Ozempic. The medication slows gastric emptying, which affects the absorption rate of other oral medications taken at the same time. Patients taking oral drugs with narrow therapeutic windows, such as thyroid hormone or certain blood thinners, should discuss timing adjustments with a pharmacist or physician before the first injection.
What Are the Alternatives to Ozempic Under Medicare?
Medicare Part D covers several GLP-1 medications beyond Ozempic, including Rybelsus (oral semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), and Victoza (liraglutide for type 2 diabetes and cardiovascular risk), each with different formulary placement across plans.
More than 90 percent of commercial and Medicare Part D plans cover Mounjaro for type 2 diabetes. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. The drug shares the same active ingredient as Zepbound, though Zepbound carries the FDA approval for chronic weight management. Coverage under Medicare follows the same rules: diabetes indication covered, weight loss indication excluded unless the GLP-1 Bridge applies.
Does Medicare Cover Wegovy or Zepbound?
Medicare Part D covers Wegovy for cardiovascular disease risk reduction in adults with obesity and established cardiovascular disease, an FDA approval granted in 2023, separate from its weight loss indication.
Zepbound (tirzepatide) is FDA-approved for chronic weight management. Medicare coverage for Zepbound follows the same weight loss exclusion that applies to Ozempic under standard Part D. But Zepbound is one of three GLP-1 options included in the Medicare GLP-1 Bridge program at the $50 copay for qualifying beneficiaries with obesity. That distinction makes Zepbound accessible for a category of Medicare patients who cannot access weight loss drugs through standard Part D.
Medicare also covers bariatric surgery under Part A and Part B for qualifying candidates with a BMI of 35 or higher and obesity-related comorbidities. Procedures including sleeve gastrectomy and Roux-en-Y gastric bypass produce durable long-term weight loss comparable to or exceeding the results seen with GLP-1 medications. Beneficiaries who do not qualify for GLP-1 coverage for weight loss may want to discuss surgical options with their care team as a covered alternative.
Medicare coverage summary for GLP-1 medications:
| Drug | Active Ingredient | Medicare Part D Coverage | GLP-1 Bridge Eligible |
| Ozempic | Semaglutide | Yes (type 2 diabetes, CVD, CKD) | No |
| Wegovy | Semaglutide | Yes (CVD risk reduction) | Yes |
| Rybelsus | Semaglutide (oral) | Yes (type 2 diabetes) | No |
| Mounjaro | Tirzepatide | Yes (type 2 diabetes) | No |
| Zepbound | Tirzepatide | No (weight loss excluded) | Yes |
Want Your Free Medicare Drug Coverage Guide From Eat Proteins?
You now know how Medicare covers Ozempic. But knowing the rules is different from knowing your specific plan’s tier, your prior authorization requirements, and whether the GLP-1 Bridge program applies to your situation. Most Medicare beneficiaries overpay for Ozempic or give up on coverage entirely because navigating Part D is genuinely confusing.
Here is what no one tells you: the rules change every year. Tier placements shift, new programs launch, and negotiated prices arrive in 2027. Staying current on all of it takes time most people do not have. The coverage specialists at Eat Proteins built a free guide that walks through every current option in plain language, from Extra Help and M3P to the Bridge program and the upcoming negotiated prices. Get it sent directly to your inbox and stop guessing.